GHRS Stock Forecast: GH Research Plc Price Predictions for 2026-2027

Last close, 20 Nov 2026
$18
−5.55% on the day

The 10 Wall Street analysts covering GH Research Plc hold a median 12-month price target of $40 — +128.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 62 of 100 as at 21 Nov 2026 — in the upper half.

Market cap
$1.2B
Ticker Nerd rank
62/ 100
Median analyst target
$40
Analysts covering
10
Revenue$0.0
Operating income−$19.4M
Net income−$15.1M
Free cash flow−$15.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−8.2%
1M
−8.5%
YTD
+38.0%
1Y
+25.3%
From 52W high
−42.8%
From 52W low
+40.4%
$12
$31
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores GH Research Plc on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
62/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
78
Momentum
71
Revisions
70
Volatility
64
Quality
60
Accruals
51
Issuance
39
Growth
27

Value (78): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Growth (27): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

GHRS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on GHRS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$20$30$40$50$60Jan 26Apr 26Jul 26Oct 26GHRSHigh $55Median $40Low $38

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says10 analysts
10
Buy
0
Hold
0
Sell
$38
Low
$40
Median
$55
High

The green dot is the last close — the median target sits +128.2% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 5 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
18 Nov 2026GuggenheimMaintainsBuy$40 → $46
17 Nov 2026HC Wainwright & Co.MaintainsBuy$65 → $55
7 Aug 2026Cantor FitzgeraldMaintainsOverweight$35 → $40
7 Aug 2026GuggenheimMaintainsBuy$34 → $40
6 Aug 2026NeedhamMaintainsBuy$32 → $39
27 July 2026Wells FargoInitiatesOverweight$44
19 May 2026HC Wainwright & Co.MaintainsBuy$70 → $65
15 May 2026Cantor FitzgeraldMaintainsOverweight$25 → $35
15 May 2026CitizensMaintainsMarket Outperform$42 → $39
6 Mar 2026CitizensMaintainsMarket Outperform—
6 Mar 2026NeedhamMaintainsBuy—
2 Mar 2026HC Wainwright & Co.MaintainsBuy—
23 Jan 2026RBC CapitalMaintainsOutperform—
6 Jan 2026Canaccord GenuityMaintainsBuy—
6 Jan 2026NeedhamMaintainsBuy—
5 Jan 2026NeedhamReiteratesBuy—
10 Nov 2025HC Wainwright & Co.MaintainsBuy—
13 Oct 2025NeedhamInitiatesBuy—
24 June 2025JMP SecuritiesReiteratesMarket Outperform—
9 May 2025GuggenheimMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for GHRS.

Market Radar

This page is one stock. Monday covers all of them.

GHRS appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

GHRS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, GH Research Plc returned +25.3% against +6.9% for the S&P 500, dividends included.

GHRS vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200Jan 26Apr 26Jul 26Oct 26GHRSS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

GHRS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
8
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
3.9×

Cheaper than 24% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−18.8%

Higher than 33% of US stocks

Return on assets
−13.0%

Higher than 24% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • GH Research Plc has a market value of $1.2B and an enterprise value of $948.8M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$62.3M.

  • Free cash flow in the twelve months to 30 June 2026: −$51.8M.

  • Shares outstanding: 68.6M.

  • GH Research Plc employs 73 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 21 Nov 2026

Data provided by Twelve Data

Peers

GHRS and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
GHRSGH Research Plc$1.2B62
MLYSMineralys Therapeutics, Inc.$1.2B13
TSHATaysha Gene Therapies, Inc.$1.2B56
GENBGenerate Biomedicines, Inc.$1.2B0
MNKDMannKind Corp.$1.2B41
OCULOcular Therapeutix, Inc.$1.2B20
NVAXNovavax, Inc.$1.2B66

Take a look at GHRS’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own GH Research Plc — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about GHRS

What is the GHRS stock price forecast for 2026-2027?

The 10 Wall Street analysts covering GH Research Plc have a median 12-month price target of $40, with estimates ranging from $38 to $55. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is GHRS stock a buy right now?

Of the 10 analysts covering GH Research Plc, 10 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks GH Research Plc 62 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank GHRS?

As at 21 Nov 2026, GH Research Plc ranks 62 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Value (78 of 100).

Will GHRS stock go up?

No one can know that. What the data says: the median 12-month target from 10 analysts implies +128.2% from the last close, and Ticker Nerd's factor model ranks GH Research Plc 62 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the GHRS stock forecast for 2030?

No analyst covering GH Research Plc publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for GHRS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $38 to $55 over the next 12 months.

How has GHRS stock performed over the past year?

GH Research Plc returned +25.3% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does GH Research Plc do?

GH Research PLC is a clinical-stage biopharmaceutical company focused on developing treatments for psychiatric and neurological disorders, with an initial emphasis on depression and treatment-resistant depression. Its current pipeline centers on mebufotenin-based therapies, including GH001, an inhalable product candidate being studied for treatment-resistant depression, bipolar II disorder, and postpartum depression, and GH002, an intravenous candidate in early clinical development.

Company

About GH Research Plc.

GH Research PLC is a clinical-stage biopharmaceutical company focused on developing treatments for psychiatric and neurological disorders, with an initial emphasis on depression and treatment-resistant depression. Its current pipeline centers on mebufotenin-based therapies, including GH001, an inhalable product candidate being studied for treatment-resistant depression, bipolar II disorder, and postpartum depression, and GH002, an intravenous candidate in early clinical development. The company is centered on research and development and works to advance novel therapeutic options for mental health conditions with significant unmet medical need. Based in Dublin, Ireland, GH Research PLC is positioned in the broader healthcare and biotechnology markets as a specialist developer of psychedelic-inspired medicines.

CEO Dr. Theis Terwey M.D. · 73 employees · Ireland · https://www.ghres.com